此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

颈胸交感神经阻滞评估用于COVID后遗症 (CeASE)

2026年10月5日 更新者:Anuj Bhatia、University Health Network, Toronto

A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Placebo Saline Injection Evaluation for Post COVID Condition: the CeASE RCT

Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per case.

A key mechanism underlying many treatment-resistant PCC symptoms appears to be dysautonomia abnormal autonomic nervous system function driven by immune-mediated sympathetic overactivity. Persistent inflammation (cytokine storms, T/B-cell dysfunction, microclots) sustains sympathetic hyperactivity, which in turn perpetuates systemic inflammation and "sickness behaviors" resembling PCC symptoms.

Current treatments including beta blockers, ivabradine, fludrocortisone, and rehabilitation are limited by variable responses, side effects, and the complication of post-exertional symptom exacerbation. Emerging therapies (SSRIs, low-dose naltrexone, antihistamines, HBOT) show promise but lack robust trial evidence.

Cervicothoracic sympathetic chain block (CSB) a local anesthetic block of the cervical and upper thoracic sympathetic ganglia is a promising intervention that reduces sympathetic outflow, improves cerebral blood supply, and lowers pro-inflammatory cytokines. Small observational studies (16 studies, 224 patients) show benefit for PCC symptoms, but all lack placebo controls and have significant methodological heterogeneity.

The proposed study aims to fill this gap with a double-blind, placebo-controlled RCT to rigorously evaluate CSB's efficacy, magnitude of benefit, and durability in PCC patients.

研究概览

详细说明

Post COVID Condition (PCC): In the wake of the COVID-19 pandemic, while many individuals recover fully from an acute COVID-19 infection, a substantial proportion experience ongoing or evolving symptoms well beyond the initial illness. These prolonged effects are broadly referred to as long COVID, also commonly referred to as the post-COVID conditions (PCC). The WHO defines long COVID as a condition following confirmed or probable SARS-CoV-2 infection, with symptoms lasting at least 2 months, typically beginning 3 months postinfection, and not explained by an alternative diagnosis. In Canada, at least 15 million people were infected with COVID-19 and 1 in 5 adults who had COVID-19 developed long-lasting symptoms after their initial infection. Of those, more than half (58.2% or about 2.1 million people) still have ongoing symptoms, defined as PCC. The annual economic burden of PCC in Canada is significant, with estimates from a Public Health Agency of Canada report suggesting a total healthcare cost between CAD 7.8 and CAD 50.6 billion. Costs per case can range from CAD 1,675 to CAD 7,340 in the first year after infection, with unvaccinated individuals experiencing higher costs and quality-adjusted life-year decrements.

Manifestations of and autonomic dysfunction in PCC: PCC presents in diverse ways and can affect multiple organ systems, including the cardiovascular, respiratory, neurological, and gastrointestinal systems. There is a range of symptoms that are encompassed within the syndrome of PCC, including fatigue, shortness of breath, chest pain, palpitations, headache, cognitive impairment ('brain fog'), rashes, anxiety, depression, gastrointestinal upset, persistent anosmia, and more with chronic fatigue and dyspnea as the most common. When cardiovascular or autonomic symptoms are present, clinicians are advised to evaluate for conditions associated with long-term sequelae of COVID-19 infection including myalgic encephalomyelitis or chronic fatigue syndrome; post-exertional malaise and post-exertional symptom exacerbation, dysautonomia with cardiac manifestations (e.g. inappropriate sinus tachycardia and postural orthostatic tachycardia syndrome (POTS: sustained and symptomatic increase in heart rate of ≥30 bpm within 10 minutes of standing without a drop in systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg)), and mast cell activation syndrome (MCAS).

While some symptoms result from tissue damage of COVID-19, persistent symptoms despite tissue repair suggest additional mechanisms in PCC. A key hypothesis implicates pathological inflammation, potentially driven by persistent viral presence, T-cell dysfunction, and B-cell hyperactivity,sustaining a hyperinflammatory state. This process contributes to cytokine storms, immune dysregulation, multiorgan inflammation, reactivation of latent pathogens, autoimmunity, and microclot formation. The sympathetic nervous system plays a critical role in immune regulation. Sympathetic fibers innervate primary and secondary lymphoid organs, and immune cells express adrenergic receptors and neuropeptides, enabling modulation by neurotransmitters released from sympathetic nerve terminals. Through these mechanisms, the SNS regulates both immune homeostasis and pathological activation. This neuroimmune cross-talk provides context for understanding the role of SNS in chronic inflammation, including PCC. Symptoms resembling autonomic dysfunction have also been observed following various viral infections such as HIV and herpes viruses, and a similar pattern is evident in PCC. Symptoms such as brain fog, fatigue, chest pain, palpitations, and severe orthostatic intolerance syndromes suggest an interaction between inflammation and autonomic hyperactivity. These findings implicate the sympathetic nervous system as a potential therapeutic target for PCC.

Many PCC symptoms that are resistant to conventional treatments have been associated with dysautonomia an abnormal functioning of the autonomic nervous system, which regulates involuntary bodily functions such as heart rate and blood pressure, respiration, and digestion. While the underlying pathophysiology of PCC remains incompletely understood, emerging evidence suggests that the autonomic dysfunction in these patients reflect immune-mediated dysregulation of the autonomic nervous system. The sympathetic branch of the autonomic nervous system plays a key role in neuroimmune communication; however, this delicate balance can be disturbed by elevated levels of pro-inflammatory cytokines, which drive sympathetic overactivity and contribute to systemic inflammation. In SARS-CoV-2 infection, this process has been well described in the literature and attributed to the cytokine storm, in which sympathetic activation is a central component of the immune response. Heightened sympathetic signaling further engages the brainstem to initiate "sickness behaviors" a cluster of physiological and behavioral responses that closely resemble the symptomatology of PCC. When this state of sympathetic hyperactivity persists over time, it may contribute to, or exacerbate, the chronic and debilitating symptoms experienced by individuals with PCC.

Treatment approaches for PCC: Medications such as ivabradine, beta blockers, midodrine, and fludrocortisone are recommended by the Canadian POTS guidelines and may improve orthostatic tolerance and cerebral perfusion in POTS patients, including those with PCC. However, responses are highly variable, access remains a barrier, and side effects can be limiting. Rehabilitation is further complicated by post-exertional symptom exacerbation (PESE), which makes structured exercise risky for many PCC patients. Preliminary studies outside of PCC suggest possible benefit from transcutaneous vagus nerve stimulation and jugular vein compression collars, but do not achieve symptom remission and benefits may wane once the user stops wearing the device.

Current treatment approaches include very few interventions backed by clinical trials, emerging therapies from patient-led research, and off-label or self-directed treatments. There is growing evidence for symptom-based pharmacologic treatments for specific PCC phenotypes including hyperbaric oxygen therapy (HBOT). Antihistamines have shown benefit in patients with MCAS features, improving symptoms in small studies. Other off-label therapies with emerging support include SSRIs, which may reduce neuroinflammation and brain fog by modulating serotonin and cytokine pathways; Maraviroc, a CCR5 antagonist that may disrupt the monocytic-endothelial-platelet axis in inflammatory states; and low-dose naltrexone, which may restore function in natural killer cells to reduce post-COVID fatigue and pain.

Role of cervicothoracic sympathetic chain block for PCC: The cervicothoracic sympathetic chain includes the superior, middle, intermediate, inferior cervical and the upper thoracic sympathetic ganglia. The inferior cervical sympathetic and the first thoracic sympathetic ganglia combine to form the stellate ganglion on each side and these ganglia are located at the level of the first rib, posterolateral to the longus colli muscle. The right stellate ganglion innervates the sinoatrial node and the right ventricle and its stimulation results in chronotropy, increased contractility, and arrhythmias. Its post ganglionic fibers also innervate the right side of the face, the right upper limb and the right lung and bronchi. The left stellate ganglion innervates the atrioventricular node and the left ventricle and its stimulation results in chronotropy, increased contractility, and arrhythmias. Its post ganglionic fibers also innervate the left side of the face, the left upper limb and the left lung and bronchi.

The cervicothoracic sympathetic chain block (CSB) is a local anesthetic block of the middle and lower cervical and upper thoracic sympathetic trunk. We have demonstrated that an ultrasound-guided injection of 5 cc of LA in the sympathetic chain at the level of the sixth cervical transverse process spreads from the fourth cervical to the first thoracic levels and blocks middle and lower cervical and upper thoracic sympathetic ganglia. We have also evaluated variations in relevant sonoanatomy for anterior and lateral approaches for CSB in a large cohort. More recently, we and others have synthesized the evidence for the role of CSBs in non-pain indications with autonomic hyperfunction including arrhythmias, peripheral vascular disease, anxiety, and other medical conditions associated with autonomic dysfunction. The effectiveness of CSB for these conditions stems from the intervention's ability to block sympathetically mediated disease manifestations. These blocks manifest their therapeutic effects through three main mechanisms: 1) blocking neural connections in the region of innervation (cervical sympathetic trunk); 2) improving blood supply to organs including the brain; and 3) reducing the plasma concentration of stress hormones and pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α,) and downregulation of NF- κB signaling. There is also evidence for persistence of therapeutic benefit from multiple consecutive CSB from a few weeks to one year despite the local anesthetics having a half-life of a few hours.

The left stellate ganglion has a greater influence on heart rate and contractility as compared to the right. Left-sided CSB have shown benefit in alleviating symptoms of PCC in cohort studies by obtunding the activity of the sympathetic nervous system outflow. A recent scoping review reported results of CSB in 16 small observational studies on 224 patients with PCC with preliminary evidence for alleviating symptoms of autonomic dysfunction in patients with PCC. However, all these studies lacked placebo or sham intervention-controlled comparators, and the reported outcomes were subjective. Further, there was considerable heterogeneity in the approach to achieving CSB in terms of laterality, injectate composition and volume, and frequency of procedures. Given the subjective nature of PCC, it is crucial to distinguish between the therapeutic benefit and the placebo effects of this intervention while also establishing the magnitude and longevity of this benefit.

To address this gap, our research group is uniquely positioned to evaluate the efficacy of CSB in a double-blind, randomized controlled trial, establishing more rigorous evidence for its potential role in the treatment of PCC.

研究类型

介入性

注册 (估计的)

78

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5T 2S8
        • 招聘中
        • Toronto Western Hospital
        • 接触:
        • 接触:
      • Toronto、Ontario、加拿大、M5S 1B3
        • 尚未招聘
        • Women's College Hospital
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion criteria

  1. Age 18 years or older
  2. PCC following COVID-19 infection with symptoms lasting for at least three months
  3. Ability to read, write, and understand English
  4. Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31), i.e. a COMPASS-31 score greater than 0. COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor.
  5. Patients should be stable on any PCC-related medications for at least four weeks.

Exclusion criteria

  1. History of co-existing conditions that are a contraindication for CSB:

    1. Unilateral vocal cord paralysis; Severe chronic obstructive pulmonary disease (FEV1 between 30-50% of predicted value)
    2. Recent myocardial infarction (within the last one year), Cardiac conduction block of any degree
    3. Glaucoma
    4. Infection or mass at injection site, bleeding disorders
  2. Comorbid conditions that could confound study results, such as:

    1. Active autoimmune disorders
    2. Pre-existing autonomic dysfunction (e.g. POTS, IST, and CRPS) prior to COVID-19
    3. Untreated psychiatric conditions (e.g. severe anxiety or PTSD requiring medication adjustments during the study period)
  3. Recent history of major surgery or cerebrovascular events within the last three months

  4. Allergy to local anesthetic; Inability to extend the neck for any reason (e.g. severe arthritis)

  5. History of prior stellate ganglion block

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Active group

The active group will have cervical sympathetic block (CSB) on both the left and right sides using up to 5 mL of 0.25% bupivacaine with epinephrine (1:200,000).

The active group will have cervical sympathetic block (CSB) on both the left and right sides using up to 5 mL of 0.25% bupivacaine with epinephrine (1:200,000). After the injection, all patients will be monitored for a minimum of 30 minutes to check for expected effects of the block and to watch for any side effects or complications.

其他名称:
  • 活动组
安慰剂比较:Placebo (Saline) Control

Participants will receive cervicothoracic sympathetic chain block (CSB) on both the left and right sides using up to 5 mL of normal saline (0.9% NaCl), by an identical ultrasound-guided approach to the active arm. After the injection, all participants will be monitored for a minimum of 30 minutes for expected effects of the block and for side effects or complications.

Participants will receive cervicothoracic sympathetic chain block (CSB) on both the left and right sides using up to 5 mL of normal saline (0.9% NaCl), by an identical ultrasound-guided approach to the active arm. After the injection, all participants will be monitored for a minimum of 30 minutes for expected effects of the block and for side effects or complications.

其他名称:
  • 5毫升生理盐水(0.9%氯化钠)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in the Modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) Symptom Severity subscale score
大体时间:One month after the final injection.

Description: The C19-YRSm Symptom Severity subscale is scored from 0 to 30, with higher scores indicating greater symptom burden. The outcome is the change from baseline in this score.

One month after the final injection.

次要结果测量

结果测量
措施说明
大体时间
C19-YRSm Symptom Severity subscale score
大体时间:Three months after the final injection.

The C19-YRSm Symptom Severity subscale is scored from 0 to 30, with higher scores indicating greater symptom burden. The outcome is the change from baseline in this score.

Three months after the final injection.
Autonomic symptom burden (COMPASS-31)
大体时间:collected at screening, one month and three months after the final injection.

Weighted total score and the six domain scores (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor).

collected at screening, one month and three months after the final injection.
Heart rate variability
大体时间:collected at screening, one month and three months after the final injection.

Heart rate variability over a five-minute recording.

collected at screening, one month and three months after the final injection.
Heart rate and blood pressure responses to autonomic challenge
大体时间:collected at screening, one month and three months after the final injection.

Valsalva manoeuvre, deep breathing, hyperventilation, and postural change (lying to sitting; sitting to standing).

collected at screening, one month and three months after the final injection.
One-minute sit-to-stand test.
大体时间:collected at screening, one month and three months after the final injection.

sitting to standing heart rate and blood pressure responses to autonomic challenge

collected at screening, one month and three months after the final injection.
Serum pro-inflammatory cytokines
大体时间:collected at screening, one month and three months after the final injection.

Measurement of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α).

collected at screening, one month and three months after the final injection.
Generalized Anxiety Disorder-7 (GAD-7)
大体时间:collected at screening, one month and three months after the final injection.

The GAD-7 is a 7-item self-report questionnaire designed to screen for and measure the severity of generalized anxiety symptoms over the previous two weeks. Patients rate how often they have been bothered by symptoms such as excessive worry, nervousness, irritability, and difficulty relaxing. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity.

collected at screening, one month and three months after the final injection.
Patient Health Questionnaire-9 (PHQ-9)
大体时间:collected at screening, one month and three months after the final injection.

The PHQ-9 is a 9-item self-administered questionnaire used to screen for and assess the severity of depressive symptoms over the preceding two weeks. It evaluates symptoms including depressed mood, loss of interest or pleasure, sleep disturbances, fatigue, appetite changes, concentration difficulties, feelings of worthlessness, psychomotor changes, and suicidal ideation. Scores range from 0 to 27, with higher scores reflecting more severe depression.

collected at screening, one month and three months after the final injection.
Hospital Anxiety and Depression Scale (HADS)
大体时间:collected at screening, one month and three months after the final injection.

The HADS is a 14-item self-report instrument developed to assess anxiety and depression in medical and outpatient settings while minimizing the influence of physical symptoms related to medical illness. It consists of two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D), each containing 7 items. Scores for each subscale range from 0 to 21, with higher scores indicating greater symptom severity.

collected at screening, one month and three months after the final injection.
EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
大体时间:collected at screening, one month and three months after the final injection.

The EQ-5D-5L is a standardized, preference-based measure of health-related quality of life developed by the EuroQol Group. It assesses health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels ranging from no problems to extreme problems/unable to perform activities. The questionnaire also includes a visual analogue scale (EQ VAS), on which participants rate their overall health from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"). Higher index and VAS scores indicate better perceived health-related quality of life.

collected at screening, one month and three months after the final injection.
Sleep Quality
大体时间:collected at screening, one month and three months after the final injection.

Pittsburgh Sleep Quality Index (PSQI)

The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire designed to assess subjective sleep quality and sleep disturbances over the previous month. The instrument comprises 19 items that generate seven component scores evaluating subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. These component scores are summed to produce a global score ranging from 0 to 21, with higher scores indicating poorer sleep quality. A global score greater than 5 is commonly used to identify clinically significant sleep disturbances.

collected at screening, one month and three months after the final injection.
Actigraphy-measured sleep-Monitoring sleep
大体时间:collected at screening, one month and three months after the final injection.

Monitoring sleep onset latency, total sleep time, number of awakenings.

collected at screening, one month and three months after the final injection.
Actigraphy-measured sleep-Monitoring daytime activities
大体时间:collected at screening, one month and three months after the final injection.

Time spent in sedentary, mild, moderate and vigorous activity.

collected at screening, one month and three months after the final injection.

其他结果措施

结果测量
措施说明
大体时间
Incidence of adverse events and serious adverse events.
大体时间:from the first injection to the three-month assessment

Events will be reported by arm, with needle-related events tabulated separately from drug-related and sympatholysis-related events.

from the first injection to the three-month assessment
Proportion of participants with a reduction of ≥4 points on the C19-YRSm Symptom Severity subscale
大体时间:one month after the final injection

The threshold is taken from the reported MCID and is not a validated responder definition

one month after the final injection
Difference in treatment effect between participants with and without postural orthostatic tachycardia syndrome (POTS), not powered for interaction; hypothesis-generating.
大体时间:one month after the final injection

Difference in treatment effect between participants with and without postural orthostatic tachycardia syndrome (POTS) not powered for interaction; hypothesis-generating.

one month after the final injection
Difference in treatment effect by baseline autonomic symptom burden
大体时间:one month after the final injection

COMPASS-31 weighted total above versus below the cohort median; not powered for interaction.

one month after the final injection
Assessment of blinding success
大体时间:Three months after the final injection

Participant and outcome assessor treatment-allocation guesses collected at the 3-month follow-up to evaluate maintenance of blinding.

Three months after the final injection

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Anuj Bhatia, MD, PhD、University Health Network, Toronto

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月19日

初级完成 (估计的)

2027年5月20日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2026年2月26日

首先提交符合 QC 标准的

2026年3月9日

首次发布 (实际的)

2026年3月12日

研究记录更新

最后更新发布 (实际的)

2026年10月9日

上次提交的符合 QC 标准的更新

2026年10月5日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data underlying the published results will be made available to investigators whose proposed use of the data has been approved by the trial steering committee

IPD 共享时间框架

Beginning nine months after publication of the primary results and ending five years thereafter.

IPD 共享访问标准

Requests should be directed to the corresponding author. Requesters must submit a methodologically sound proposal and sign a data sharing agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅